Volume | 2,483,864 |
|
|||||
News | - | ||||||
Day High | 1.35 | Low High |
|||||
Day Low | 1.31 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Akebia Therapeutics Inc | AKBA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.325 | 1.31 | 1.35 | 1.33 | 1.36 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,221 | 2,483,864 | $ 1.32 | $ 3,279,832 | - | 0.65 - 2.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:23:00 | 2 | $ 1.34 | USD |
Akebia Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
278.47M | 209.37M | - | 194.62M | -51.93M | -0.25 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Akebia Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AKBA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.37 | 1.435 | 1.31 | 1.37 | 2,222,235 | -0.0225 | -1.64% |
1 Month | 2.47 | 2.48 | 1.31 | 1.64 | 7,552,326 | -1.12 | -45.45% |
3 Months | 1.70 | 2.48 | 1.31 | 1.71 | 4,989,818 | -0.3525 | -20.74% |
6 Months | 0.85 | 2.48 | 0.7801 | 1.58 | 3,195,958 | 0.4975 | 58.53% |
1 Year | 0.65 | 2.48 | 0.65 | 1.44 | 2,497,431 | 0.6975 | 107.31% |
3 Years | 3.05 | 4.33 | 0.241 | 1.32 | 3,776,453 | -1.70 | -55.82% |
5 Years | 6.41 | 13.78 | 0.241 | 2.42 | 3,485,878 | -5.06 | -78.98% |
Akebia Therapeutics Description
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. |